Crizanlizumab-tmca

Crizanlizumab-tmca (pronounced as kri-zan-li-zu-mab-tmca) is a medication used in the treatment of sickle cell disease. It is a monoclonal antibody that works by blocking the interaction of P-selectin with its ligand, which is a key step in the vaso-occlusive process.

Etymology

The name "Crizanlizumab-tmca" is derived from the following components: "Criz" for the company that developed it, Novartis' code name for the drug, "anli" for anti, "zu" for human, "mab" for monoclonal antibody, and "tmca" for the specific target, P-selectin.

Usage

Crizanlizumab-tmca is used to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. It is administered by intravenous infusion.

Related Terms

• Monoclonal antibody
• P-selectin
• Sickle cell disease
• Vaso-occlusive crisis

See Also

• List of monoclonal antibodies
• List of drugs used in the treatment of sickle cell disease

References

• FDA approves crizanlizumab-tmca for sickle cell disease. (2019, November 15). FDA. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizanlizumab-tmca-sickle-cell-disease
• Crizanlizumab (Adakveo). (2020, January). Drug and Therapeutics Bulletin, 58(1), 10–12. https://doi.org/10.1136/dtb.2020.000005

External links

• Medical encyclopedia article on Crizanlizumab-tmca
• Wikipedia's article - Crizanlizumab-tmca

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski